Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q7RTY3

UPID:
PRS45_HUMAN

ALTERNATIVE NAMES:
Serine protease 45, pseudogene; Testis serine protease 5

ALTERNATIVE UPACC:
Q7RTY3; A3KN77

BACKGROUND:
The protein known as Putative serine protease 45, with alternative names Serine protease 45, pseudogene, and Testis serine protease 5, plays a significant role in the protease enzyme family. These enzymes are essential for processing proteins in various physiological processes, including metabolism and the immune system. The detailed role of Putative serine protease 45 in these processes is an area of active research.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Putative serine protease 45 holds promise for identifying novel therapeutic approaches. As research unfolds, targeting this protease could lead to breakthroughs in treating diseases where protein processing is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.